These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11936707)

  • 1. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.
    Al-Shurbaji A; Säwe J
    Eur J Clin Pharmacol; 2002 Feb; 57(12):877-81. PubMed ID: 11936707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
    Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
    Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
    Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
    Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
    Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
    Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.
    Eap CB; Bender S; Gastpar M; Fischer W; Haarmann C; Powell K; Jonzier-Perey M; Cochard N; Baumann P
    Ther Drug Monit; 2000 Apr; 22(2):209-14. PubMed ID: 10774635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
    Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
    Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.
    Masimirembwa CM; Gustafsson LL; Dahl ML; Abdi YA; Hasler JA
    Br J Clin Pharmacol; 1996 Apr; 41(4):344-6. PubMed ID: 8730982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity.
    Persson J; Hasselström J; Maurset A; Oye I; Svensson JO; Almqvist O; Scheinin H; Gustafsson LL; Almqvist O
    Eur J Clin Pharmacol; 2002 Feb; 57(12):869-75. PubMed ID: 11936706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.
    Hellman K; Roos E; Osterlund A; Wahlberg A; Gustafsson LL; Bertilsson L; Fredrikson S
    Br J Clin Pharmacol; 2003 Sep; 56(3):337-40. PubMed ID: 12919185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
    Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
    Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
    Kuhlmann JB; Wensing G; Kuhlmann J
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.